Heparanase Inhibition by Pixatimod (PG545): Basic Aspects and Future Perspectives

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Heparanase is a key enzyme in cancer progression, regulating the extracellular environment through heparan sulfate (HS) cleavage.
• Heparanase activity and HS-binding protein signaling promote tumor cell proliferation, invasion, metastasis, and angiogenesis.

Purpose of the Study:

• To evaluate pixatimod, a novel heparanase inhibitor, as a potential anti-cancer therapeutic.
• To investigate the mechanisms by which pixatimod inhibits pro-cancerous processes.
• To assess the efficacy of pixatimod in preclinical cancer models and its potential in combination therapies.

Main Methods:

• In vitro and in vivo studies using xenograft and syngeneic mouse cancer models.
• Analysis of biological samples to confirm heparanase targeting and anti-cancer effects.
• Combination studies with approved anti-cancer drugs and clinical trials.

Main Results:

• Pixatimod demonstrated potent anti-cancer activity across a wide range of mouse cancer models.
• Inhibition of heparanase by pixatimod effectively blocked cancer cell proliferation, invasion, metastasis, angiogenesis, and epithelial-mesenchymal transition.
• Biological sample analyses confirmed in vivo heparanase targeting and the broad spectrum of anti-cancer effects.

Conclusions:

• Pixatimod is a potent inhibitor of heparanase with broad-spectrum anti-cancer activity.
• The agent shows promise as a monotherapy and in combination with other anti-cancer drugs, including checkpoint inhibitors.
• Clinical trials are ongoing to further evaluate pixatimod's safety and efficacy in cancer patients.